Drug Profile
Influenza virus delta NS1 vaccine
Alternative Names: deltaFLU LAIV; deltaFLU quadrivalent LAIV; FluVacc; FluVacc - DNS1; Fluvacc delta NS1; FLUVACCdelNS1; FluVaccΔNS1; GHB01L1; GHB04L1; GHB11L1; GHB16L2; H5N1 influenza virus vaccine; Influenza A virus vaccine H1N1; Intranasal H5N1 vaccine - Avir Green Hills Biotechnology; Pandemic avian flu vaccine - Avir Green Hills Biotechnology; Seasonal influenza vaccine deltaFLU; Seasonal influenza virus vaccine Green Hills - BiotechnologyLatest Information Update: 03 Sep 2021
Price :
$50
*
At a glance
- Originator Green Hills Biotechnology
- Developer Vivaldi Biosciences
- Class Antivirals; Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Influenza virus infections
Most Recent Events
- 03 Sep 2021 Vivaldi Biosciences plans a phase II trial for Influenza virus infection (Vivaldi Biosciences pipeline, September 2021)
- 12 Oct 2018 Influenza virus delta NS1 vaccine is still in phase II trials for Influenza virus infections in Austria (Vivaldi Biosciences product development, October 2018)
- 04 Apr 2018 Pharmacodynamics data from a preclinical study in Influenza virus infections released by Vivaldi Biosciences